Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard antipsychotic therapy Clear all
Not yet recruiting Not applicable Interventional

Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area

NCT07570875
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ketogenic foodstuffs, Standard of Care Oral antipsychotics, Standard of care long acting injectable medication for bipolar disorder
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Montgomery, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 5:05 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of ANAVEX3-71 in Adults With Schizophrenia

NCT06245213
View directory record Official record
Conditions
Schizophrenia
Interventions
ANAVEX3-71 oral capsules, Placebo oral capsules
Drug
Lead sponsor
Anavex Life Sciences Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

NCT05542264
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Phase 3 Interventional

An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCT06067984
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms in Schizophrenia
Interventions
Study App
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Phase 3 Interventional

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCT05838625
View directory record Official record
Conditions
Schizophrenia
Interventions
CT-155, Digital Control
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
54
States / cities
Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 23, 2026, 5:05 AM EDT
Completed No phase listed Observational

Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment

NCT00538122
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
24 Holter Monitor Recording
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2009 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

NCT05402111
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 23, 2026, 5:05 AM EDT
Recruiting Phase 3 Interventional

Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)

NCT06333990
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Quetiapine Fumarate, TAU
Drug
Lead sponsor
Foundation for Advancing Veterans' Health Research
Other
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Albuquerque, New Mexico • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 23, 2026, 5:05 AM EDT
Terminated Not applicable Interventional

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

NCT01420575
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Visual Decision Aid and Shared Decision Making Model, Usual Care
Behavioral
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 23, 2026, 5:05 AM EDT
Terminated Phase 2Phase 3 Interventional

A Long-Term, Open-Label, Study on Schizophrenia

NCT01129674
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 5:05 AM EDT
Not listed Phase 4 Interventional

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

NCT02282085
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Drug
Lead sponsor
Matt Byerly
Other
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Early Phase 1 Interventional

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

NCT04280965
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Quetiapine Fumarate, Standard of care meducations
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 23, 2026, 5:05 AM EDT
Recruiting Phase 3 Interventional

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

NCT07184619
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Evenamide 15 mg bid, Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417
View directory record Official record
Conditions
Schizophrenia
Interventions
Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional Results available

The PACE/PACENET Behavioral Health Laboratory Project

NCT02440594
View directory record Official record
Conditions
Depression
Interventions
Enhanced BHL Program Services, Standard BHL Program Services
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
2,432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 23, 2026, 5:05 AM EDT
Terminated Phase 4 Interventional Results available

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

NCT00712270
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 23, 2026, 5:05 AM EDT
Withdrawn Phase 4 Interventional

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318
View directory record Official record
Conditions
Psychosis, Agitation, Delirium
Interventions
ziprasidone, Standard therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Phase 3 Interventional

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

NCT01192867
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Antipshychotics (Standard of Care)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 23, 2026, 5:05 AM EDT
Recruiting Phase 4 Interventional

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

NCT07483294
View directory record Official record
Conditions
Psychosis; Acute
Interventions
risperidone, aripiprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional Results available

Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia

NCT00406718
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Med-eMonitor, PharmCAT, Treatment as Usual
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Phase 1 Interventional

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder

NCT01116830
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Standard Antipsychotic Therapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional

Promoting Adherence to Treatment in Schizophrenia

NCT01125267
View directory record Official record
Conditions
Schizophrenia
Interventions
multifamily group-adherence, multifamily group-standard
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Granada Hills, California
Source: ClinicalTrials.gov public record
Updated May 17, 2010 · Synced Sep 23, 2026, 5:05 AM EDT
Terminated Phase 3 Interventional Results available

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

NCT03892889
View directory record Official record
Conditions
Schizophrenia
Interventions
Abilify MyCite®
Combination Product
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
68
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 23, 2026, 5:05 AM EDT